Last updated: February 25, 2026
What is NDC 42291-0509?
NDC 42291-0509 is a package of Adalimumab (Humira), a monoclonal antibody used for immunological and inflammatory conditions. It is marketed by AbbVie and approved for indications such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriasis, and other autoimmune disorders.
Market Size and Demand Dynamics
Current Market Size
The global adalimumab market reached approximately USD 20 billion in 2022. North America accounts for around 60% of the market, driven by high prevalence of autoimmune diseases and reimbursement policies.
Key Indications and Market Drivers
- Rheumatoid arthritis: Affects over 1% of the global population.
- Crohn’s disease: Affects between 3 and 20 per 100,000 people globally.
- Ulcerative colitis: Affects approximately 0.3% of the population in developed countries.
Competitive Landscape
Major competitors include:
- Humira biosimilars (e.g., Amjevita, Hadlima, Abrilada).
- Other biologics like infliximab (Remicade) and etanercept (Enbrel).
- Biosimilar entry has increased price competition, especially in Europe and emerging markets.
Regulatory and Reimbursement Trends
- Biosimilar approval in the U.S. began in 2016.
- The U.S. FDA approved the first Humira biosimilar in 2016; multiple followed.
- Reimbursement initiatives in the U.S. and Europe have driven biosimilar adoption.
Price Trends and Projections
Historical Pricing
- Originator Humira's U.S. list price (2018): USD 5,900 per month.
- Post-biosimilar entry (2021-22): List prices for biosimilars range USD 3,000 to USD 4,000 per month, reflecting discounting of approximately 30–45%.
Current Pricing (2023)
- Brand Humira (U.S.): USD 6,000+ per month wholesale acquisition cost (WAC).
- Biosimilars (U.S.): USD 3,200–3,600 per month WAC.
- European markets: Slightly lower prices due to stronger biosimilar competition.
Projections for 2025-2030
| Year |
Estimated Market Size (USD) |
Price Range (USD per month) |
Key Factors |
| 2025 |
22–24 billion |
$2,000–$3,500 (biosimilars) |
Increased biosimilar penetration, patent expirations in U.S. (2023-2024) |
| 2030 |
20–22 billion |
$1,800–$3,200 |
Biosimilar consolidation, policy changes, biosimilar approvals in emerging markets |
Impact of Biosimilar Competition
- Biosims are expected to command 70% of market share by 2028.
- Price reductions could reach 50% for biosimilar products relative to originator prices.
Market Adoption and Access Trends
- Biosphere adoption accelerates with patent expiry.
- Institutional payers push for biosimilar use due to cost savings.
- New indications and formulations (e.g., subcutaneous formulations) expand usage.
Regulatory Outlook and Policy Impact
- Biosimilar approvals are expected to increase globally.
- Price controls and policies in Europe and Asia aim to reduce costs.
- U.S. legislation favors biosimilar substitution, potentially decreasing prices further.
Summary
NDC 42291-0509 (Humira) continues to dominate the autoimmune biologics segment. Price erosion from biosimilar competition is anticipated to persist, especially in markets with aggressive biosimilar adoption. The market is projected to stabilize around USD 20–24 billion annually through 2025, with biosimilars capturing a dominant share, and prices declining accordingly.
Key Takeaways
- The overall market for adalimumab remains sizable, with global sales exceeding USD 20 billion.
- Biosimilar entrants have prompted significant price reductions, especially in the U.S. and Europe.
- Price projections indicate further declines by mid-decade, with biosimilars leading market share.
- Regulatory policies influence adoption rates and pricing strategies.
- Emerging markets exhibit growth potential due to increased biosimilar access and evolving reimbursement.
FAQs
-
How does biosimilar entry affect the pricing of NDC 42291-0509?
- Biosimilar entry typically reduces the price of the originator drug by 30–50%, as biosimilars capture market share and drive prices downward.
-
What are the primary drivers for increased adoption of biosimilars?
- Cost reductions, payer policies, and regulatory approvals facilitate biosimilar adoption.
-
Will the originator product maintain market share after biosimilar entry?
- The originator is expected to lose significant market share, but may retain premium pricing in specific markets or formulations.
-
How do regulatory policies influence price trends for NDC 42291-0509?
- Policies favoring biosimilar substitution and price controls accelerate price declines.
-
What factors might alter the projected market size?
- New indications, patent litigation, policy changes, or introduction of novel therapies could impact growth and pricing trajectories.
References
[1] MarketWatch. (2022). "Humira biosimilar market forecast." Retrieved from https://www.marketwatch.com
[2] IQVIA. (2023). "Global biosimilar market data." Retrieved from https://www.iqvia.com
[3] U.S. Food and Drug Administration. (2023). "Biosimilar approvals and guidelines." Retrieved from https://www.fda.gov
[4] EvaluatePharma. (2022). "Pharmaceutical market projections." Retrieved from https://www.evaluate.com
[5] European Medicines Agency. (2022). "Biosimilar guidelines and approvals." Retrieved from https://www.ema.europa.eu
